Compare ABT & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABT | NVS |
|---|---|---|
| Founded | 1888 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 222.8B | 266.5B |
| IPO Year | N/A | 1991 |
| Metric | ABT | NVS |
|---|---|---|
| Price | $124.65 | $139.00 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 4 |
| Target Price | ★ $146.61 | $118.00 |
| AVG Volume (30 Days) | ★ 5.5M | 1.6M |
| Earning Date | 01-21-2026 | 01-30-2026 |
| Dividend Yield | ★ 2.02% | 1.86% |
| EPS Growth | ★ 141.97 | N/A |
| EPS | ★ 7.96 | 7.30 |
| Revenue | $43,843,000,000.00 | ★ $56,372,000,000.00 |
| Revenue This Year | $7.57 | $9.38 |
| Revenue Next Year | $7.96 | $2.69 |
| P/E Ratio | ★ $15.68 | $19.07 |
| Revenue Growth | 6.37 | ★ 12.88 |
| 52 Week Low | $110.86 | $96.91 |
| 52 Week High | $141.23 | $140.18 |
| Indicator | ABT | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 70.63 |
| Support Level | $123.85 | $138.39 |
| Resistance Level | $125.33 | $140.18 |
| Average True Range (ATR) | 2.09 | 1.48 |
| MACD | 0.04 | 0.48 |
| Stochastic Oscillator | 44.97 | 87.29 |
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.